A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome

ConclusionsAzacitidine and decitabine are both associated with improved outcomes compared to BSC. The available indirect evidence comparing the two agents warrants very low certainty and cannot reliably confirm the superiority of either agent. Head-to-head trials are needed. In the meantime, the choice of agent should be driven by patient preferences, adverse effects, drug availability, and cost.
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research